Improving progression-free and overall survival in patients with cancer: A potential role for bisphosphonates

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 5, 2011, Pages 749-762

  Lipton, Allan ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

anticancer; bisphosphonate; bone; skeletal related events; zoledronic acid

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; CELECOXIB; CLODRONIC ACID; DENOSUMAB; DEXAMETHASONE; DOCETAXEL; GEMCITABINE; IBANDRONIC ACID; LETROZOLE; MEVALONIC ACID; PAMIDRONIC ACID; PLACEBO; PREDNISONE; THALIDOMIDE; ZOLEDRONIC ACID;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG UPTAKE; EARLY INTERVENTION; EVIDENCE BASED MEDICINE; HUMAN; IMMUNOREACTIVITY; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; MICROMETASTASIS; MULTIPLE MYELOMA; NONHUMAN; OVERALL SURVIVAL; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RECURRENT CANCER; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SOLID TUMOR; TREATMENT DURATION; UROGENITAL TRACT CANCER;

DIPHOSPHONATES; DISEASE-FREE SURVIVAL; HUMANS; NEOPLASMS;

EID: 79952609241     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.538384     Document Type: Review

References (85)

1. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243s-6249s (Pubitemid 44703797)
2. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-76 (Pubitemid 32452017)
3. Fogelman I, Blake GM, Blamey R, et al. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int 2003;14:1001-6 (Pubitemid 40824271)
4. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001;19:3306-11 (Pubitemid 32642182)
5. Hadji P. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol 2009;69:73-82
6. Smith MR Treatment-related osteoporosis in men with prostate cancer. Clin Cancer Res 2006;12:6315-6319s
7. Lipton A, Cook RJ, Major P, et al. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 2007;12:1035-43 (Pubitemid 350007015)
8. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008;19:420-32
9. Lipton A, Cook R, Saad F, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008;113:193-201 (Pubitemid 351976401)
10. Saad F. New research findings on zoledronic acid: survival, pain, and anti-tumour effects. Cancer Treat Rev 2008;34:183-92 (Pubitemid 351384327)
11. Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001;91:1191-200
12. Brufsky AM, Bosserman LD, Caradonna RR, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 2009;9:77-85
13. Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003;98:962-9 (Pubitemid 37022096)
14. Trinkaus M, Simmons C, Myers J, et al. Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting. Support Care Cancer 2010;18:197-203
15. Aviles A, Nambo MJ, Neri N, et al. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 2007;24:227-30 (Pubitemid 350135975)
16. Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010;21:2188-94
17. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314-21
18. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613-21 (Pubitemid 38715767)
19. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol 2003;21:3150-7 (Pubitemid 46606297)
20. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-68
21. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-82 (Pubitemid 38807610)
22. Hirsh V, Major PP, Lipton A, et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 2008;3:228-36 (Pubitemid 351654321)
23. Terpos E, Berenson J, Cook RJ, et al. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Leukemia 2010;24:1043-9
24. Costa L, Cook R, Body JJ, et al. Zoledronic acid treatment delays disease progression and improves survival in patients with bone metastases from solid tumors and elevated levels of bone resorption. Presented at the IX International Meeting on Cancer Induced Bone Disease; 28-31 October 2009; Arlington, VA, USA
25. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360:679-91
26. Morgan G, Davies F, Gregory W, et al. Evaluating the effects of zoledronic acid (ZOL) on overall survival (OS) in patients (Pts) with multiple myeloma (MM): results of the Medical Research Council (MRC) Myeloma IX study. Presented at the 46th Annual Meeting of the American Society of Clinical Oncology; 4-8 July 2010; Chicago, IL, USA
27. Zarogoulidis K, Boutsikou E, Zarogoulidis P, et al. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer 2009;125:1705-9
28. Pandya KJ, Gajra A, Warsi GM, et al. Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer. Lung Cancer 2010;67:330-8
29. Thompson K, Rogers MJ, Coxon FP, Crockett JC. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol 2006;69:1624-32
30. Hosfield DJ, Zhang Y, Dougan DR, et al. Structural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesis. J Biol Chem 2004;279:8526-9 (Pubitemid 38295905)
31. Coxon JP, Oades GM, Kirby RS, Colston KW. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int 2004;94:164-70 (Pubitemid 38980328)
32. Monkkonen H, Auriola S, Lehenkari P, et al. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol 2006;147:437-45 (Pubitemid 43292286)
33. Raikkonen J, Crockett JC, Rogers MJ, et al. Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro. Br J Pharmacol 2009;157:427-35
34. Ferretti G, Fabi A, Carlini P, et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology 2005;69:35-43 (Pubitemid 41207056)
35. Yamada J, Tsuno NH, Kitayama J, et al. Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation. J Surg Res 2009;151:115-20
36. Caraglia M, Santini D, Marra M, et al. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 2006;13:7-26
37. Santini D, Martini F, Fratto ME, et al. In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother 2009;58:31-8
38. Aft R, Naughton M, Trinkaus K, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010;11:421-8
39. Rack BK, Jueckstock J, Genss E-M, et al. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res 2010:1807-13
40. Nesbitt SA, Horton MA. Trafficking of matrix collagens through bone-resorbing osteoclasts. Science 1997;276:266-9 (Pubitemid 27172687)
41. Coxon FP, Thompson K, Roelofs AJ, et al. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 2008;42:848-60
42. Roelofs AJ, Coxon FP, Ebetino FH, et al. Fluorescent risedronate analogs reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res 2009;25:606-16
43. Coscia M, Quaglino E, Iezzi M, et al. Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med 2009: published online 10 October 2009, doi 10.1111/j.1582-4934.2009.00926.x
44. Korpal M, Yan J, Lu X, et al. Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med 2009;15:960-6
45. Pan B, Farrugia AN, To LB, et al. The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). J Bone Miner Res 2004;19:147-54 (Pubitemid 41295147)
46. Rachner TD, Singh SK, Schoppet M, et al. Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Lett 2010;287:109-16
47. Viereck V, Emons G, Lauck V, et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 2002;291:680-6 (Pubitemid 34687400)
48. Green J, Clezardin P. The molecular basis of bisphosphonate activity: a preclinical perspective. Semin Oncol 2010;37(Suppl 1):S3-11
49. Neville-Webbe HL, Gnant M, Coleman RE. Potential anticancer properties of bisphosphonates. Semin Oncol 2010;37(Suppl 1):S53-65
50. Powles T, Paterson A, McCloskey E, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006;8:R13
51. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998;339:357-63 (Pubitemid 28363797)
52. Ha TC, Li H. Meta-analysis of clodronate and breast cancer survival. Br J Cancer 2007;96:1796-801 (Pubitemid 46912011)
53. Jaschke A, Bastert G, Solomayer EF, et al. Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow-a longtime follow-up [abstract 529]. J Clin Oncol 2004;22(Suppl):9
54. Gnant M, Mlineritsch B, Stoeger H, et al. Mature results from ABCSG-12: adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer [abstract 533]. J Clin Oncol 2010;28(Suppl):75s
55. LLombarto A, Frassoldati A, Paija O, et al. Effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow up [abstract 213]. ASCO Breast Cancer Symposium, 8-10 October 2009; San Fransisco, CA, USA
56. Coleman RE, Winter MC, Cameron D, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010;102:1099-105 Preliminary neoadjuvant data from the AZURE trial point to a significant anticancer effect ofzoledronic acid in patients with early breast cancer.
57. Shiozawa Y, Havens AM, Pienta KJ, Taichman RS. The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 2008;22:941-50 (Pubitemid 351689875)
58. Lin A, Park J, Melisko M, et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and occult tumor cells in bone marrow. Poster presented at the 30th Annual San Antonio Breast Cancer Symposium; 13-16 December 2007; San Antonio, TX, USA
59. Solomayer EF, Gebauer G, Hirnle P, et al. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Poster presented at the 31st Annual San Antonio Breast Cancer Symposium; 10-14 December 2008; San Antonio, TX, USA
60. Santini D, Vincenzi B, Avvisati G, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 2002;8:1080-4 (Pubitemid 34517643)
61. Santini D, Vincenzi B, Dicuonzo G, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003;9:2893-7 (Pubitemid 36993246)
62. Dicuonzo G, Vincenzi B, Santini D, et al. Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J Interferon Cytokine Res 2003;23:649-54 (Pubitemid 37452905)
63. Mystakidou K, Katsouda E, Parpa E, et al. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 2005;22:195-201 (Pubitemid 41003454)
64. Saad F, Lipton A. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int 2005;96:964-9 (Pubitemid 41531396)
65. Zaghloul MS, Boutrus R, El-Hossieny H, et al. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol 2010;15:382-9
66. Hoshi S, Numahata K, Ono K. The impact of zoledronic acid therapy in survival of bladder cancer patients with bone metastasis [abstract e15096]. Presented at the 46th Annual Meeting of the American Society of Clinical Oncology; 4-8 July 2010; Chicago, IL, USA
67. Dearnaley DP, Mason MD, Parmar MK, et al. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 2009;10:872-6
68. National Cancer Institute, 2008. Phase II/III randomized pilot study of androgen suppression (AS) alone versus AS in varying combinations with zoledronate, docetaxel, prednisolone, and/or celecoxib in patients with locally advanced or metastatic prostate cancer. Available from: http://www.cancer.gov/ search/ViewClinicalTrials.aspx?cdrid=455008&version=HealthProfessional& protocolsearchid=8017001 [Last accessed 6 August 2010]
69. US National Institutes of Health, 2009. RADAR trial-randomized androgen deprivation and radiotherapy. Available from: http://clinicaltrials.gov/ct2/ show/NCT00193856 [Last accessed 15 April 2010]
70. US National Institutes of Health, 2008. Zoledronate plus standard therapy compared with placebo plus standard therapy to prevent bone metastases in patients with recurrent prostate cancer that has no symptoms. Available from: http://clinicaltrials.gov/ct2/show/NCT00005073 [Last accessed 15 April 2010]
71. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996;334:488-93 (Pubitemid 26067736)
72. Brincker H, Westin J, Abildgaard N, et al. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Br J Haematol 1998;101:280-6 (Pubitemid 28261115)
73. Laakso M, Lahtinen R, Virkkunen P, Elomaa I; Finnish Leukaemia Group. Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Br J Haematol 1994;87:725-9 (Pubitemid 24264643)
74. Lahtinen R, Laakso M, Palva I, et al; Finnish Leukaemia Group. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992;340:1049-52
75. McCloskey EV, Dunn JA, Kanis JA, et al. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol 2001;113:1035-43 (Pubitemid 32634773)
76. McCloskey EV, MacLennan IC, Drayson MT, et al; MRC Working Party on Leukaemia in Adults. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Haematol 1998;100:317-25 (Pubitemid 28131063)
77. Menssen HD, Sakalova A, Fontana A, et al. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 2002;20:2353-9 (Pubitemid 34441663)
78. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377-87 (Pubitemid 33759002)
79. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-44 (Pubitemid 37238631)
80. Terpos E, Sezer O, Croucher PI, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009;20:1303-17
81. Berenson JR, Dimopoulos MA, Chen Y-M. Zoledronic acid may improve survival compared to pamidronate in patients with MM and high BALP levels: univariate and multivariate models of hazard ratios [abstract 3589]. Blood 2006;108
82. Henry D, von Moos R, Vadhan-Raj S, et al. A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Paper presented at the ECCO 15-34th ESMO Multidisciplinary Congress; 20-24 September 2009; Berlin, Germany
83. Musto P, Petrucci MT, Bringhen S, et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer 2008;113:1588-95
84. Zometa [package insert]. East Hanover, NJ: Novartis pharmaceuticals Corporation; 2009. Available from: http://www.accessdata.fda.gov/drugsatfda- docs/label/2009/021223s018lbl.pdf
85. Hirsh V. Skeletal disease contributes substantially to morbidity and mortality in patients with lung cancer. Clin Lung Cancer 2009;10:223-9